CMS Carey & Allende and Cooley advised HealthAtom, while Villarino E Ilharreborde and Wilson Sonsini Goodrich & Rosati advised Kayyak Ventures in the transaction. The Chilean...
HealthAtom’s $10 Million Series A Financing Round
AstraZeneca’s Acquisition of CinCor Pharma
Covington & Burling advised AstraZeneca. Skadden represented Centerview Partners LLC, the exclusive financial advisor to CinCor Pharma Inc. Cooley advised CinCor Pharma. CinCor Pharma Inc. (“CinCor”)...
Fenbi’s HK$198 Million Listing on The HKSE
Cooley advised the underwriters involved in the listing while Wilson Sonsini Goodrich & Rosati represented Fenbi. Fenbi, an internet-born test preparation company, proposed the listing of...
Chiesi Farmaceutici’s Acquisition of Amryt Pharma Plc
Dechert advised Chiesi Farmaceutici S.p.A. Gide Loyrette Nouel represented BNP Paribas. Amryt Pharma was advised by Cooley. Italian pharmaceutical company Chiesi Farmaceutici has signed a definitive agreement to acquire Amryt Pharma in...
Kite’s Acquisition of Tmunity
Cooley advised Tmunity on the deal. Tmunity, a clinical-stage biotechnology company, announced its agreement to sell to Kite, a global biopharmaceutical company. The acquisition will provide...
STAR CM’s HK$390 Million IPO
Cooley, Zhong Lun and Maples and Calder, advised STAR CM on the deal. STAR CM, a variety program intellectual property creator and operator, announced its HK$390 million...
Cryofocus Medtech’s HK$210 Million IPO
Cooley advised the joint sponsors and underwriters on the deal while O’Melveny represented Cryofocus Medtech (Shanghai) Co., Ltd. Cryofocus Medtech announced its HK$210 million ($27 million) initial...
Snyk’s $196.5 Million Series G Funding
Cooley advised Snyk on the deal while Orrick represented the investors. Snyk, a cybersecurity software startup, announced its $196.5 million Series G funding round. The round was...
645 Ventures’ Formation of 645 Ventures IV and Launch of 645 Ventures Select I
Cooley advised 645 Ventures on the deal. 645 Ventures, an early-stage venture capital firm, announced the formation of its oversubscribed fourth fund, 645 Ventures IV, and...
Akeso’s US$5 Billion Licensing Agreement With Summit Therapeutics Title
Sidley advised Akeso Inc. on the deal. Akeso Inc. announced a high-profile US$5 billion collaboration and licensing agreement with Summit Therapeutics Inc. to out-license its breakthrough bispecific...
Amgen’s Acquisition of Horizon Therapeutics
Cooley LLP and Matheson LLP advised Horizon, while Sullivan & Cromwell LLP and William Fry LLP advised Amgen. Debevoise & Plimpton LLP advised JP Morgan. Macfarlanes...
Avant’s $250 Million Financing from Ares
Cooley advised Avant on the deal. Avant, a credit-first financial technology company, announced that it secured $250 million of corporate debt and redeemable preferred equity from...